JMP Downgrades Indevus Pharma (IDEV) to Market Perform
IDEV Hot Sheet
Rating Summary:0 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 0 | Down: 1 | New: 1
JMP Securities downgrades Indevus Pharmaceuticals (Nasdaq: IDEV) from Market Outperform to Market Perform.
Indevus Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the acquisition, development, and commercialization of products to treat conditions in urology and endocrinology in the United States.
Indevus Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the acquisition, development, and commercialization of products to treat conditions in urology and endocrinology in the United States.
You May Also Be Interested In
- UPDATE: UBS Downgrades Wisconsin Energy (WEC) to Neutral; Taking Some Off The Table
- Barclays Cuts Price Target and Estimates on NetApp (NTAP); Disappointing Qtr, But There Is Hope
- Barclays Maintains an 'Equalweight' on Trina Solar (TSL); Waiting on Growth in Gross Margins and Stabilized Opex
Create E-mail Alert Related Categories
DowngradesRelated Entities
JMP SecuritiesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
